Skip Nav Destination
Abstract CT130: Evidence for synergistic immune responses in the first-in-human (FIH) combination of B cell-activating immunotherapy (IO) with anti-PD1 immune checkpoint inhibitor nivolumab (N) as 2nd-line therapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)
Cancer Res (2020) 80 (16_Supplement): CT130.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer
- Fen Wang
- Mingyi Yang
- Weichi Luo
- Qing Zhou
Journal of the National Cancer Center (2022) 2 (4): 243.
- Tania Crombet Ramos
- Orestes Santos Morales
- Grace K. Dy
- Kalet León Monzón
- Agustín Lage Dávila
Frontiers in Oncology (2021) 11